Vigamox 0.5% Eye Drops

Moxifloxacin 0.5% Eye prep
5mg/ml
ALCON LABORATORIES, INC.
Pack size 5ml Dropper Bottle
Dispensing mode POM
Source USA
AgentModern Pharmaceutical Co.
Retail Price 41.00 AED

Indications

Vigamox 0.5% Eye Drops is used for: Bacterial Conjunctivitis. This drug is indicated to increase tear production in patients whose tear production is suppressed due to ocular inflammation associated with dry eye syndrome (keratoconjunctivitis sicca).

Adult Dose

Ophthalmic Bacterial conjunctivitis Adult: As 0.5% soln: Instill 1 drop into the affected eye(s) bid-tid for 7 days. It can be used concomitantly with artificial tears, allowing a 15 minute interval between products.

Child Dose

Ophthalmic Bacterial conjunctivitis Child: >1 yr: Instill 1 drop into the affected eye(s) tid for 7 days.

Renal Dose

Administration

Contra Indications

Patients with a history of hypersensitivity to Moxifloxacin, to other Quinolones or to any of the components in this medication

Precautions

As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. To prevent contamination do not touch the tip of the dropper to eye, eyelid or any surface of of the affected eye. Keep the bottle tightly closed after use. Lactation: Unknown whether drug is excreted in breast milk; use with caution

Pregnancy-Lactation

Pregnancy There are no available human data establishing a drug associated risk; however, when moxifloxacin was administered to rats during pregnancy and throughout lactation at doses associated with maternal toxicity, decreased neonatal body weights, increased incidence of skeletal variations (rib and vertebra combined), and increased fetal loss were observed Advise pregnant women of potential risk to fetus Lactation Not known if moxifloxacin is present in human milk Based on animal studies in rats, moxifloxacin may be excreted in human milk Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on the breastfed child from drug or from the underlying maternal condition

Interactions

Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine. Potentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.

Adverse Effects

Side effects of Moxifloxacin 0.5% Eye prep : 1-10% Conjunctivitis, Dry eye, Fever, Increased cough, Infection, Ocular discomfort, Ocular hyperemia, Ocular pain, Ocular pruritus, Otitis media.Pharyngitis, Rash, Rhinitis, Subconjunctival hemorrhage.Tearing

Mechanism of Action

Moxifloxacin inhibits the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination.

Note

Vigamox 0.5% 5mg/ml Eye Drops manufactured by ALCON LABORATORIES, INC.. Its generic name is Moxifloxacin 0.5% Eye prep. Vigamox 0.5% is availble in United Arab Emirates. Farmaco UAE drug index information on Vigamox 0.5% Eye Drops is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Moxifloxacin 0.5% Eye prep :